<DOC>
	<DOCNO>NCT01866007</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic ( body medication ) comparability guselkumab lyophilize liquid formulation . Also evaluate pharmacokinetic comparability liquid formulation guselkumab deliver prefilled syringe UltraSafe Passive Delivery System [ PFS-U ] prefilled syringe facilitate injection device [ PFS FID ] ) follow single subcutaneous ( SC ) administration 100 mg guselkumab healthy participant .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetic Comparability Guselkumab ( CNTO1959 ) When Delivered 2 Different Devices 2 Formulations Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , parallel study ( group participant treat time ) guselkumab healthy participant . Approximately 140 participant randomly assign ratio 2:2:2:1 4 treatment group : Group 1 ( SC injection lyophilize formulation ) , Group 2 ( subcutaneous [ SC ] injection liquid formulation PFS-U ) , Group 3 ( SC injection liquid formulation PFS-FID ) , Group 4 ( IV infusion liquid formulation ) . The study consist 3 phase : screening ( 4 week ) , open-label treatment inpatient follow ( 1 week ) outpatient follow ( 11 week ) . Safety evaluation include assessment adverse event , vital sign , physical examination , electrocardiogram , injection-site reaction , clinical laboratory test . The total duration study participant approximately 16 week .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy participant clinically significant abnormality Have weight range 60 kg 90 kg male participant ; weight range 50 kg 80 kg female participant Have body mass index ( BMI ) 18.5 kg/m2 29.0 kg/m2 Agrees protocoldefined use effective contraception Participant history clinically significant medical illness include liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance , ophthalmological disorder , neoplastic disease , urinary tract disease , dermatological disease Currently know malignancy history malignancy Participant know suspect intolerance hypersensitivity biologic medication know allergy clinically significant reaction murine , chimeric , human proteins monoclonal antibody antibody fragment Have Bacillus CalmetteGu√©rin ( BCG ) vaccination within 12 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Guselkumab</keyword>
	<keyword>CNTO1959</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>UltraSafe Passive Delivery System ( PFS-U )</keyword>
	<keyword>Prefilled syringe facilitate injection device ( PFS FID )</keyword>
</DOC>